* CervoMed Inc reported a quarterly adjusted loss of 55 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -70 cents. The mean expectation of five analysts for the quarter was for a loss of 41 cents per share. Wall Street expected results to range from -50 cents to -31 cents per share.
* Revenue rose 27.1% to $1.94 million from a year ago; analysts expected $3.07 million.
* CervoMed Inc's reported EPS for the quarter was a loss of 55 cents.
* The company reported a quarterly loss of $4.75 million.
* CervoMed Inc shares had fallen by 16.8% this quarter and gained 59.1% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 8.3% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for CervoMed Inc is 63.00 This summary was machine generated from LSEG data November 12 at 01:38 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.41 -0.55 Missed
Jun. 30 2024 -0.31 -0.27 Beat
Mar. 31 2024 -0.39 -0.41 Missed
Dec. 31 2023 -0.29 -0.38 Missed
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。